Private clinical services can look attractive to a pharmacy owner because they offer a different source of income from the existing dispensing business. However, adding a service is not the same as adding profit. Consultations need qualified people, suitable premises, appropriate authorisation, stock, documentation and reliable arrangements when a patient cannot be treated. A platform can support some of that work without removing the underlying responsibilities.
Pharmadoctor is worth examining in that context. The useful question is not whether digital pharmacy services are fashionable, but whether a particular service can meet a genuine local need at a sustainable cost. This guide draws on provider information checked on 18 October 2026 and uses an explicitly illustrative model rather than predicting a pharmacy's earnings.
What Pharmadoctor actually adds
Pharmadoctor describes clinical service packages and digital consultation tools, known as eTools, which support pharmacy-based services and incorporate relevant patient group directions within applicable packages. Its own explanation describes a move beyond stand-alone documentation towards digitally supported service delivery and patient discovery. That positioning is relevant, but is not independent evidence of increased revenue for an individual pharmacy. See Pharmadoctor's explanation of its service model.
During a demonstration, follow one service from initial enquiry to completed record. Ask which package components are included, what requires additional payment, who updates clinical materials and what happens when the underlying service changes. Establish whether training, consultation support, marketing materials and patient-facing visibility are included in the specific quotation, rather than inferring this from the wider brand.
Start with a defined local need
A sensible launch begins with evidence that suitable patients need a service the pharmacy can deliver well. Existing enquiries, unfulfilled requests and conversations with local healthcare organisations can help shape that assessment. These are planning inputs, not permission to imply endorsement or enter informal referral arrangements with undisclosed financial incentives.
Describe the intended patient group, opening hours, access arrangements and alternatives. A service offered only during the busiest dispensing period may be less accessible than the business plan suggests. Likewise, a long list of available services can create an impression of capacity that disappears when the only appropriately trained pharmacist is absent.
A narrow, reliable initial offer is often easier to evaluate than launching several services simultaneously. It also makes it possible to identify whether weak uptake reflects low demand, inconvenient availability, confusing information or a poorly designed booking process.
A purchased package is not prescribing authority
The legal mechanism for supplying or administering a medicine must be appropriate to the actual service. NHS Specialist Pharmacy Service guidance distinguishes patient group directions from prescribing and explains that a person treated under a PGD must meet its criteria. Buying access to software or documentation does not confer independent prescribing status or permit departures from those criteria. See the SPS introduction to PGDs.
Before launch, establish the applicable authorisation, professional eligibility, competence requirements, documentation and review arrangements. Confirm how locum and newly appointed staff are assessed for the specific service. A general statement that someone is registered should not replace that service-level check.
The practical operating procedure also needs to cover the patient who is excluded, requires a different assessment or declines treatment. That outcome is part of providing care, not a failed sale that staff should be encouraged to reverse.
Model the complete consultation, not just the supply
An illustrative pharmacy might charge GBP55 for a particular eligible service, with GBP18 of direct product and consumable costs and GBP2 of payment and transaction costs. That leaves GBP35 before allocating staff time, premises, software, training and other overheads. These figures are fictional and do not represent Pharmadoctor pricing or any named clinical service.
Suppose the service occupies 30 minutes of pharmacist time, including preparation and documentation, and the pharmacy allocates GBP20 of staffing cost to that episode. The remaining GBP15 is not final profit. It still needs to contribute towards the service's fixed costs and the time spent on enquiries, unsuitable bookings, follow-up and stock management.
At 40 completed episodes, that simplified contribution is GBP600. A launch plan that assumes all 40 occur immediately, without additional administration or wasted stock, is fragile. Test a lower-volume case and a higher-time-per-consultation case before committing to annual expenditure.
Count work that does not result in treatment
A financially honest model includes assessments where supply is inappropriate. Decide how charges are explained before the appointment, including what happens when the patient is not eligible for the advertised service. Avoid a fee structure that surprises people after they have disclosed sensitive information or encourages clinicians to treat to justify a charge.
Measure enquiries, bookings, attendance, clinically appropriate service completion and onward referral separately. These stages reveal different problems. Many enquiries with few bookings may reflect unclear pricing or availability; many exclusions may indicate that the public-facing service description needs revision.
The objective is not to maximise the proportion receiving a medicine. It is to offer appropriate care while understanding the resources required to do so. Include consultation outcomes and patient understanding alongside the financial measures.
Staffing and stock can determine the result
Consider what happens to the rest of the pharmacy while a clinician is consulting. A service may require additional cover, a different rota or protected appointment windows. Moving an existing employee into the consultation room does not make their time free if another task becomes delayed or requires replacement capacity.
Stock decisions deserve equal attention. Model ordering quantities, expiry, storage, replenishment and any service-specific handling requirements. A theoretical product margin can disappear when demand is intermittent or stock must be purchased before appointments are confirmed.
Make absence arrangements explicit. A cancelled clinic may require patient communication, refunds where appropriate and alternative advice. The package subscription can continue even while the pharmacy cannot offer the service, so availability should be part of the commercial assessment.
Test documentation and follow-up before advertising
Use a synthetic patient scenario to check record completeness, access permissions, printing or export, corrections and communication with another clinician when appropriate. Establish what remains accessible after a package expires and how records can be retained in a usable form.
Also test a difficult scenario: an incomplete consultation, a patient who cannot be contacted, a suspected adverse reaction or a request for further advice after the original episode. The service needs an accountable process, not merely an entry in a digital record.
Clinical learning can support preparation, but it is separate from service-specific authorisation and competence. Broader resources such as iatroX Academy should complement, not replace, the relevant pharmacy training, guidance and governance arrangements.
Run a controlled commercial pilot
Agree a review date and a small set of measures before launch. Record total staff time, service availability, appropriate completed episodes, patient experience, direct costs and the contribution remaining after those costs. Keep launch expenditure separate from recurring costs so that a quiet first month does not obscure the long-term picture.
Do not interpret released minutes as a cash saving unless expenditure actually falls. Equally, a service can be worthwhile without producing large immediate profits if it improves access sustainably and supports the pharmacy's agreed direction. Those benefits should be stated explicitly rather than hidden inside an inflated revenue forecast.
Pharmadoctor is therefore best evaluated as a possible component of a carefully designed clinical service. The decision should turn on local need, operational readiness and measured economics, not the number of packages available to buy.
FAQs
Does buying a Pharmadoctor package make a pharmacist an independent prescriber?
No. Software and service documentation do not confer prescribing qualifications. The lawful mechanism, professional competence and service-specific authorisation must be established separately.
How should a pharmacy estimate the profitability of a private service?
Start with collected fees, deduct direct product and transaction costs, then account for staffing, unsuccessful assessments, administration, stock losses and fixed service costs. Use conservative demand assumptions.
Should a pharmacy launch several private services at once?
Not necessarily. A limited initial service can be easier to staff, govern and evaluate. Expansion should follow demonstrated demand and reliable delivery rather than the availability of additional packages.
Explore clinical learning to complement profession-specific pharmacy development with iatroX Academy.